One Capital Management LLC Buys 12,030 Shares of Globus Medical, Inc. $GMED

One Capital Management LLC grew its stake in shares of Globus Medical, Inc. (NYSE:GMED) by 41.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 41,053 shares of the medical device company’s stock after acquiring an additional 12,030 shares during the quarter. One Capital Management LLC’s holdings in Globus Medical were worth $3,584,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Advisory Services Network LLC bought a new stake in shares of Globus Medical during the 3rd quarter worth $26,000. EverSource Wealth Advisors LLC increased its stake in shares of Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the period. SBI Securities Co. Ltd. increased its stake in shares of Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after buying an additional 167 shares during the period. Parallel Advisors LLC increased its stake in shares of Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after buying an additional 173 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Globus Medical during the third quarter worth approximately $36,000. 95.16% of the stock is currently owned by institutional investors.

Globus Medical Stock Performance

Shares of NYSE GMED opened at $78.28 on Wednesday. Globus Medical, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $101.40. The stock has a fifty day moving average of $86.88 and a 200-day moving average of $88.39. The stock has a market cap of $10.63 billion, a PE ratio of 18.20, a price-to-earnings-growth ratio of 1.65 and a beta of 0.95.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. During the same period in the previous year, the business earned $0.68 earnings per share. The firm’s revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, sell-side analysts predict that Globus Medical, Inc. will post 4.74 EPS for the current year.

Analyst Ratings Changes

GMED has been the subject of several recent analyst reports. Needham & Company LLC raised their target price on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Truist Financial set a $115.00 target price on Globus Medical in a report on Wednesday, February 25th. Wells Fargo & Company dropped their price target on Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, Barclays lifted their price target on Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $106.36.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.